{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Vitamin B12"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K192064",
    "Predicate Device Reference 510(k) Number(s)": [
        "K140496"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CDD"
    ],
    "Summary Letter Date": "July 31, 2019",
    "Summary Letter Received Date": "August 5, 2019",
    "Submission Date": "September 25, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1810"
    ],
    "Regulation Name(s)": [
        "Vitamin B12 test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Vitamin B12"
    ],
    "Specimen Type(s)": [
        "Serum",
        "SST Serum",
        "Lithium Heparin Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Competitive immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON Vitamin B12 CLIA assay for quantitative measurement of Vitamin B12 in serum, SST serum, and lithium heparin plasma",
    "Indications for Use Summary": "Quantitative determination of Vitamin B12 in human serum, SST serum, and lithium heparin plasma to aid in the diagnosis and treatment of anemias of gastrointestinal malabsorption; results should be used with other clinical or laboratory data for patient management",
    "fda_folder": "Clinical Chemistry"
}